Cargando…

Preclinical Testing of a Vaccine Candidate against Tularemia

Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tul...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Ragavan Varadharajan, Ma, Zhuo, Sunagar, Raju, Bhatty, Vivek, Banik, Sukalyani, Catlett, Sally V., Gosselin, Edmund J., Malik, Meenakshi, Bakshi, Chandra Shekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405390/
https://www.ncbi.nlm.nih.gov/pubmed/25897786
http://dx.doi.org/10.1371/journal.pone.0124326
_version_ 1782367634827771904
author Suresh, Ragavan Varadharajan
Ma, Zhuo
Sunagar, Raju
Bhatty, Vivek
Banik, Sukalyani
Catlett, Sally V.
Gosselin, Edmund J.
Malik, Meenakshi
Bakshi, Chandra Shekhar
author_facet Suresh, Ragavan Varadharajan
Ma, Zhuo
Sunagar, Raju
Bhatty, Vivek
Banik, Sukalyani
Catlett, Sally V.
Gosselin, Edmund J.
Malik, Meenakshi
Bakshi, Chandra Shekhar
author_sort Suresh, Ragavan Varadharajan
collection PubMed
description Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tularemia vaccine development have included inactivated, live attenuated, or subunit vaccines. Shortcomings in each of these approaches have hampered the development of a suitable vaccine for prevention of tularemia. Recently, we reported an oxidant sensitive mutant of Ft LVS in putative EmrA1 (FTL_0687) secretion protein. The emrA1 mutant is highly sensitive to oxidants, attenuated for intramacrophage growth and virulence in mice. We reported that EmrA1 contributes to oxidant resistance by affecting the secretion of antioxidant enzymes SodB and KatG. This study investigated the vaccine potential of the emrA1 mutant in prevention of respiratory tularemia caused by Ft LVS and the virulent SchuS4 strain in C57BL/6 mice. We report that emrA1 mutant is safe and can be used at an intranasal (i. n.) immunization dose as high as 1x10(6) CFU without causing any adverse effects in immunized mice. The emrA1 mutant is cleared by vaccinated mice by day 14–21 post-immunization, induces minimal histopathological lesions in lungs, liver and spleen and a strong humoral immune response. The emrA1 mutant vaccinated mice are protected against 1000–10,000LD(100) doses of i.n. Ft LVS challenge. Such a high degree of protection has not been reported earlier against respiratory challenge with Ft LVS using a single immunization dose with an attenuated mutant generated on Ft LVS background. The emrA1 mutant also provides partial protection against i.n. challenge with virulent Ft SchuS4 strain in vaccinated C57BL/6 mice. Collectively, our results further support the notion that antioxidants of Ft may serve as potential targets for development of effective vaccines for prevention of tularemia.
format Online
Article
Text
id pubmed-4405390
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44053902015-05-07 Preclinical Testing of a Vaccine Candidate against Tularemia Suresh, Ragavan Varadharajan Ma, Zhuo Sunagar, Raju Bhatty, Vivek Banik, Sukalyani Catlett, Sally V. Gosselin, Edmund J. Malik, Meenakshi Bakshi, Chandra Shekhar PLoS One Research Article Tularemia is caused by a gram-negative, intracellular bacterial pathogen, Francisella tularensis (Ft). The history weaponization of Ft in the past has elevated concerns that it could be used as a bioweapon or an agent of bioterrorism. Since the discovery of Ft, three broad approaches adopted for tularemia vaccine development have included inactivated, live attenuated, or subunit vaccines. Shortcomings in each of these approaches have hampered the development of a suitable vaccine for prevention of tularemia. Recently, we reported an oxidant sensitive mutant of Ft LVS in putative EmrA1 (FTL_0687) secretion protein. The emrA1 mutant is highly sensitive to oxidants, attenuated for intramacrophage growth and virulence in mice. We reported that EmrA1 contributes to oxidant resistance by affecting the secretion of antioxidant enzymes SodB and KatG. This study investigated the vaccine potential of the emrA1 mutant in prevention of respiratory tularemia caused by Ft LVS and the virulent SchuS4 strain in C57BL/6 mice. We report that emrA1 mutant is safe and can be used at an intranasal (i. n.) immunization dose as high as 1x10(6) CFU without causing any adverse effects in immunized mice. The emrA1 mutant is cleared by vaccinated mice by day 14–21 post-immunization, induces minimal histopathological lesions in lungs, liver and spleen and a strong humoral immune response. The emrA1 mutant vaccinated mice are protected against 1000–10,000LD(100) doses of i.n. Ft LVS challenge. Such a high degree of protection has not been reported earlier against respiratory challenge with Ft LVS using a single immunization dose with an attenuated mutant generated on Ft LVS background. The emrA1 mutant also provides partial protection against i.n. challenge with virulent Ft SchuS4 strain in vaccinated C57BL/6 mice. Collectively, our results further support the notion that antioxidants of Ft may serve as potential targets for development of effective vaccines for prevention of tularemia. Public Library of Science 2015-04-21 /pmc/articles/PMC4405390/ /pubmed/25897786 http://dx.doi.org/10.1371/journal.pone.0124326 Text en © 2015 Suresh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Suresh, Ragavan Varadharajan
Ma, Zhuo
Sunagar, Raju
Bhatty, Vivek
Banik, Sukalyani
Catlett, Sally V.
Gosselin, Edmund J.
Malik, Meenakshi
Bakshi, Chandra Shekhar
Preclinical Testing of a Vaccine Candidate against Tularemia
title Preclinical Testing of a Vaccine Candidate against Tularemia
title_full Preclinical Testing of a Vaccine Candidate against Tularemia
title_fullStr Preclinical Testing of a Vaccine Candidate against Tularemia
title_full_unstemmed Preclinical Testing of a Vaccine Candidate against Tularemia
title_short Preclinical Testing of a Vaccine Candidate against Tularemia
title_sort preclinical testing of a vaccine candidate against tularemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405390/
https://www.ncbi.nlm.nih.gov/pubmed/25897786
http://dx.doi.org/10.1371/journal.pone.0124326
work_keys_str_mv AT sureshragavanvaradharajan preclinicaltestingofavaccinecandidateagainsttularemia
AT mazhuo preclinicaltestingofavaccinecandidateagainsttularemia
AT sunagarraju preclinicaltestingofavaccinecandidateagainsttularemia
AT bhattyvivek preclinicaltestingofavaccinecandidateagainsttularemia
AT baniksukalyani preclinicaltestingofavaccinecandidateagainsttularemia
AT catlettsallyv preclinicaltestingofavaccinecandidateagainsttularemia
AT gosselinedmundj preclinicaltestingofavaccinecandidateagainsttularemia
AT malikmeenakshi preclinicaltestingofavaccinecandidateagainsttularemia
AT bakshichandrashekhar preclinicaltestingofavaccinecandidateagainsttularemia